drugset
drugset / Trial / NCT05032833

Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

NCT05032833 ↗

Phase 1 Completed 36 enrolled Beckley Psytech Limited
RandomizedSequentialQuadruple-blindTreatment

Summary

The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects

Timeline

Start
2021-09-22
Primary completion
2022-07-07
Completion
2022-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mebufotenin Small molecule — Intranasal

Indications

No indication recorded.